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Open accAbstract Background: Adrenal insufﬁciency, or relative insufﬁciency, might partly explain
increased mortality rates in nephroblastoma and neuroblastoma survivors after unilateral
adrenalectomy.
Objective: To assess adrenal function and its metabolic effects in survivors after adrenalec-
tomy.
Methods: In this cross-sectional study, 67 adult long-term survivors of nephroblastoma, 36
survivors of neuroblastoma and 49 control subjects participated. Adrenal function was
assessed by a 1 lg short Synacthen-test. Levels of cortisol, adrenocorticotrophic hormone
(ACTH), low (LDL-C) and high-density lipoprotein-cholesterol (HDL-C), triglycerides, apo-
lipoprotein-B, glucose and insulin were assessed in blood samples taken at baseline. In addi-
tion, cortisol levels were assessed after 30 (t = 30) and 60 min. Homoeostatic Model
Assessment (HOMA) was calculated.
Results: Adrenal insufﬁciency was not present in survivors. Interestingly, baseline serum cor-
tisol levels were higher in survivors after unilateral adrenalectomy (mean 503 nmol/l) (N = 46)
than in survivors with both adrenals intact (mean 393 nmol/l, P = 0.002) (N = 52), and than
in controls (mean 399 nmol/l, P = 0.013) (N = 49). After correcting for age, sex and use of
oral oestrogens, unilateral adrenalectomy was independently associated with elevated baseline
cortisol and ACTH levels. Baseline cortisol levels were positively associated with triglycerides
(P < 0.001), LDL-C (P = 0.004), apolipoprotein-B (P < 0.001) and HOMA (P = 0.008).
Conclusions: No adrenal insufﬁciency was observed in survivors of nephroblastoma and neu-
roblastoma. Survivors treated with unilateral adrenalectomy had relatively high basal cortisol
and ACTH levels, indicating a higher central setpoint of the hypothalamic-pituitary-adrenal46
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1160 M. van Waas et al. / European Journal of Cancer 48 (2012) 1159–1166axis. This higher setpoint was associated with lipid concentrations and insulin resistance and
can therefore inﬂuence the cardiovascular risk proﬁle in long-term survivors of nephroblas-
toma and neuroblastoma.
 2012 Elsevier Ltd.Open access under the Elsevier OA license. 1. Introduction
Over the past decades, childhood cancer survival
rates have increased signiﬁcantly. Approximately 75%
of children diagnosed with cancer are cured and become
long-term survivors. For children diagnosed with neph-
roblastoma or neuroblastoma 5-year survival is approx-
imately 84% and 64%, respectively. Increased long-term
survival has led to increasing absolute numbers of survi-
vors: to date one in 640 young adults is a childhood can-
cer survivor.1 Therefore the recognition of late eﬀects
has become more relevant. In nephroblastoma and neu-
roblastoma survivors, especially those treated with
radiotherapy, the risk for developing late adverse events
like second malignant neoplasms and pulmonary, ortho-
paedic and cardiovascular events, musculoskeletal late
eﬀects, cardiac toxicity, reproductive health problems
and renal dysfunction is signiﬁcant.2–4 Due to poor sur-
vival, reports on late eﬀects in intensively treated long-
term neuroblastoma survivors are mainly based on case
series and small cohorts.
Although endocrine sequelae are the most common
late eﬀects,5–15 little is known about the long-term endo-
crine eﬀects in survivors of nephroblastoma or neuroblas-
toma. Increased mortality rates as compared to the
general age-matched population have been reported in
childhood cancer survivors, which are partly related to
the above-mentioned documented late eﬀects.16 However
unexpected deaths occur and to date it is unknown
whether adrenal insuﬃciency following surgery, radio-
therapy and/or chemotherapy for nephroblastoma or
neuroblastoma is an important denominator of this
excess mortality rate later in life. Abdominal surgery is
part of the treatment for nephroblastoma and neuroblas-
toma. In themajority of nephroblastoma patients, unilat-
eral total nephrectomy, often including unilateral
adrenalectomy, is performed. In neuroblastoma patients,
adrenalectomy is performedwhen the tumour is located in
the adrenal gland. Bilateral adrenalectomy is associated
with high morbidity and mortality rates as a consequence
of adrenal insuﬃciency.17,18 It is unknown whether adre-
nal function after unilateral adrenalectomy declines over
time by ageing, especially in survivors who were also
treated with chemotherapy or local radiotherapy. We
hypothesised that a subset of neuroblastoma and nephro-
blastoma survivors has a subnormal adrenal function and
therefore performed a study on the inﬂuence of adminis-
tered treatment on adrenal function in long term nephro-
blastoma and neuroblastoma survivors. Additionally, toevaluate the possible altered eﬀect of the hypothalamic-
pituitary-adrenal (HPA) axis on the metabolic status in
these survivors, we assessed the inﬂuence of cortisol on
lipids and insulin resistance parameters.
2. Methods
2.1. Patients
All long-term (P5 years after cessation of treatment)
adult survivors of childhood nephroblastoma and neu-
roblastoma, treated between 1961 and 2004 in the Eras-
mus MC-Sophia Children’s Hospital are followed
prospectively at the Late Eﬀects Registration outpatient
clinic. They were invited to participate in this cross-sec-
tional study. Informed consent was obtained according
to the Helsinki declaration19 and the study was
approved by the local medical ethical committee.
Of the 88 adult long-term survivors of nephroblas-
toma who were alive and currently living in The Nether-
lands, 67 participated, six were lost to follow-up, 13
refused to participate and two survivors were not able
to visit the outpatient clinic at the appointed time inter-
val. Adult survivors with neuroblastoma stage 4s who
did not receive surgery, radiotherapy or chemotherapy
were excluded from this study. Of the 50 eligible neuro-
blastoma survivors, 36 survivors participated, ﬁve were
lost to follow-up, six refused to participate and three
females were pregnant at the time of the study. Informa-
tion on disease and treatment was obtained from our
local database and medical records. Data regarding
(partial) unilateral adrenalectomy were obtained from
pathology reports. As to date limited normal values
for young adults are available, we recruited a control
group, consisting of siblings, friends or neighbours, pref-
erably of the same sex and within an age range of 5 years
of their related survivor. This group was designed as a
socio-demographically similar comparison population.
Information regarding smoking status and socio-
economic status (deﬁned by the highest level of educa-
tional attainment) was collected using a questionnaire.
Height was measured to the nearest millimetre using a
Harpenden Stadiometer and weight was measured with-
out shoes and clothes but in underwear to the nearest
0.1 kg with a standard clinical balance. Body mass index
(BMI) was calculated as weight in kilograms divided by
the squared length in metres. Survivors and controls
participated in this study from October 2009 until
March 2011.
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To evaluate adrenal function, a low dose (1 lg) short
ACTH stimulation-test was performed both in survivors
and control subjects. ACTH stimulation-tests were
started in the morning, all before 10:00 am. Subjects
were resting during 1 h and during the test. Fasting
blood samples were taken from one and the same intra-
venous-cannula at baseline, after 30 minutes (t = 30)
and after 60 min (t = 60). One millilitre of Synacthen
solution 250 lg/ml (Deﬁante Farmaceutica S.A., Portu-
gal) was added to 249 ml of sterile solution of NaCl
0.9%. One millilitre of this solution, corresponding to
1 lg of Synacthen, was administered intravenously after
the baseline blood sample was taken. Serum cortisol lev-
els were measured at the baseline, t = 30 and t = 60. At
t = 30, cortisol levels higher than 440 nmol/l were con-
sidered normal, adrenal insuﬃciency was deﬁned as cor-
tisol levels below 440 nmol/l at t = 30.20 In addition,
ACTH was measured in the sample taken at the
baseline.2.3. Laboratory measurements
Serum cortisol (nmol/l), adrenocorticotrophic hor-
mone (ACTH) (pmol/l), androstenedione (adione)
(nmol/l), dehydroepiandosterone-sulphate (DHEAs)
(lmol/l), insulin (p/mol/l), testosterone (nmol/l), dehy-
dro-epiandosterone (DHEA) (nmol/l), 17-hydroxypro-
gesterone (17OHP) (nmol/l), triglycerides, high-density
lipoprotein-cholesterol (HDL-C), low-density lipopro-
tein-cholesterol (LDL-C), glucose and apolipoprotein-
B (Apo-B) (g/l) were measured. Assays and intra- and
inter coeﬃcients of variation are described in Supple-
mentary text. Homoeostatic Model Assessment
(HOMA) was calculated as a measure of insulin
resistance.212.4. Statistics
Statistical analysis was performed with the Statistical
Package for Social Sciences (SPSS 17.0, Chicago, IL,
United States). Data are expressed as means and stan-
dard deviations, unless speciﬁed otherwise. Independent
Sample t-tests were used to compare results in survivors
and controls and in subgroups. The associations
between cortisol levels and various treatment parame-
ters and baseline characteristics were analysed using
multiple linear regression modelling. Cortisol, ACTH,
triglycerides and glucose levels were normally distrib-
uted after log-transformation. Beta’s of logtransformed
variables are expressed in percentages. Age and sex were
added to all models and inﬂuence of BMI was evaluated
as previously recommended.22 Oestrogens, as the com-
ponent of hormonal contraception or as oral supple-
mentals in oestrogen deﬁcient women, are known toincrease serum levels of cortisol-binding globulin
(CBG) resulting in higher total serum cortisol levels.
Accordingly, serum cortisol concentrations do not cor-
relate well with cortisol production rates unless the cor-
tisol binding globulin concentration is accounted for.23
Twenty-nine out of 73 females (9/25 controls, 20/48 sur-
vivors) in our study used oral oestrogens. Therefore,
oral oestrogen use was added to the model. Further-
more, three subjects were using ﬂuticasone (one survivor
with both adrenals intact, one survivor who underwent
adrenalectomy, one control subject) and one survivor
who underwent adrenalectomy was using hydrocorti-
sone cream. A subanalysis was performed excluding
these survivors. In the ﬁrst model we added a dummy
variable for patients with intact adrenals and a dummy
variable for patients who had undergone an adrenalec-
tomy. In the second model, we added cumulative dose
of anthracyclines, vincristine actinomycine, being trea-
ted with cyclophosphamide or not (dichotomous vari-
able) and radiotherapy administered to the abdomen
or to the contralateral adrenal gland. The variables
smoking (smoker, non-smoker or former smoker) and
socio-economic status (ordinal variable) were added to
both models, but these factors were not signiﬁcant.
Additionally, multivariate analyses were performed to
assess the inﬂuence of cortisol levels on metabolic
parameters. Models were corrected for age, sex, socio-
economic status, BMI, diagnosis, abdominal radiother-
apy and cumulative dose of administered chemotherapy.
P-values <0.05 (two-tailed) were considered statistically
signiﬁcant.3. Results
3.1. Survivors and controls
Sixty-seven long-term adult nephroblastoma survi-
vors (28 females) and 36 neuroblastoma survivors (21
females) participated in this study. Forty-eight percent
of survivors had a sibling or friend willing to participate,
resulting in 49 participating control subjects (23
females). Thirty-six of them were siblings and 13 were
partners or friends of the survivors. The main reason
for survivors not to bring a control-subject was the
inability or unwillingness of siblings or neighbours to
participate as they had to take a day oﬀ at work. Base-
line and treatment characteristics and status of the adre-
nal glands are shown in Table 1. In survivors who
underwent adrenalectomy the tumour was located in
or close to the adrenal gland, in survivors treated with
partial adrenalectomy the tumour was located at the
upper part of the kidney and in survivors treated with-
out adrenalectomy the tumour was located at the lower
part of the kidney. Synacthen stimulation-tests were
performed in 93/103 survivors and in 48/49 controls
and baseline cortisol levels were available in 101/103
Table 1
Baseline characteristics of study participants.
Nephroblastoma Neuroblastoma Controls
N 67 36 49
Male/female 39/28 15/21 26/23
Age at follow-up (years) 30.2 (18.8–50.8) 29.6 (20.4–46.2) 32.7 (18.0–61.8)
Age at diagnosis (years) 3.3 (0.0–12.7) 0.8 (0.0–11.7) n.a.
Follow-up time (years)a 26.2 (6.4–48.9) 27.8 (15.0–44.4) n.a.
Stage
1 32 6 n.a.
2 13 17
3 11 8
4 3 2
5 1 0
Unknown 7 3
Surgery (n) 67 36 n.a.
Unilateral adrenalectomy 26 13 n.a.
Partial adrenalectomy 7 0
No adrenalectomy 31 23
Unknown 3 0
Radiotherapy (n) 35 12 n.a.
Hemi-abdomen 20 0 n.a.
Abdomen 5 7
Kidney 7 0
Lung(s) 3 0
Thorax 0 2
Spine 0 1
Neck 0 1
Cumulative dose (Gy) 25 (15–40) 20 (10–30) n.a.
Chemotherapy (n) 59 31 n.a.
N Cumulative dose N Cumulative dose
Vincristin (mg/m2) 51 22.0 (6.0–93.0) 16 22.8 (5.0–65.0) n.a.
Actinomycin D (mg/m2) 48 10.9 (0.1–24.8) 0 n.a. n.a.
Anthracyclines (mg/m2) 18 250 (100–450) 12 210 (100–315) n.a.
Cyclophosphamide (mg/m2) 2 3825 (250–7400) 29 7350 (3150–45990) n.a.
Cisplatin (mg/m2) 0 0 6 450 (270–630) n.a.
Teniposide (mg/m2) 0 0 6 500 (300–700) n.a.
Dacarbazine (mg/m2) 2 14.7 (13.5–15.8) 0 0 n.a.
Iphosphamide (mg/m2) 2 33,000 (30,000–36,000) 0 0 n.a.
Data expressed as median (range).
a Time after cessation of treatment. n.a. = not applicable, Gy = gray.
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mation regarding adrenalectomy was not available, they
were therefore excluded in the relevant analysis.
3.2. Baseline levels
Mean baseline cortisol level in nephroblastoma and
neuroblastoma survivors was 450 nmol/l and in controls
399 nmol/l (P = 0.141). Two survivors (one nephroblas-
toma and one neuroblastoma) and two control subjects
had cortisol levels higher than 1000 nmol/l at baseline.
Baseline cortisol levels were not diﬀerent between nephro-
blastoma or neuroblastoma survivors (mean 461 versus
mean 429, P = 0.44, Appendix Table 1). Interestingly,
baseline serum cortisol levels were higher in survivors
after unilateral adrenalectomy compared with survivors
without adrenalectomy (P = 0.002), and also higherwhen
compared with controls (P = 0.013) (Fig. 1a). The per-
centage of oestrogen users was not signiﬁcantly diﬀerentbetween the two survivor subgroups (P = 0.203). After
correcting for confounders the eﬀect of adrenalectomy
remained signiﬁcant (P = 0.010) in the total group
(Table 2), in the subanalysis excluding females on oral
oestrogens (b = 28.3, P = 0.002) and in the subanalysis
excluding survivors who were currently using corticoste-
roids (b = 20.0,P = 0.019).Cumulative dose of anthracy-
clines (b = 0.0002, P = 0.995), vincristine (b = 0.4,
P = 0.121) and actinomycin (b = 0.8, P = 0.297), being
treated with cyclophosphamide (b = 3.3, P = 0.723),
abdominal radiotherapy (b = 2.3, P = 0.789) and
radiotherapy administered to the contralateral adrenal
gland (b = 17.2, P = 0.244) were not signiﬁcant.
Mean ACTH levels were 5.3 pmol/l both in controls
and in survivors with both adrenals intact, and were
7.8 pmol/l in survivors after adrenalectomy. After cor-
recting for age, sex, oral oestrogen use and BMI, adre-
nalectomy was positively associated with baseline
ACTH levels both in the total group (b = 49.2,
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Fig. 1a. Baseline cortisol levels. Data shown as means and individual values. NMales. d Females no oral oestrogens. s Females oral oestrogens.
Table 2
Inﬂuence of determinants on serum cortisol levels in survivors and controls.
Model 1 Cortisol t = 0a Cortisol t = 30b Cortisol t = 60c
Variable b (%) 95% CI P-value b (%) 95% CI P-value b (%) 95% CI P-value
Age (per 10 years) 0.4 1.0, 0.3 0.291 0.1 0.3, 0.4 0.644 0.2 0.2, 0.07 0.339
Sex (male) 24.3 9.0, 41.8 0.001 0.5 6.3, 7.9 0.890 0.8 9.5, 8.7 0.859
Oestrogen use 85.7 55.6, 121.7 <0.001 33.6 21.0, 47.4 <0.001 49.2 31.4, 69.2 <0.001
BMI 0.1 1.7, 1.4 0.851 0.8 0.1, 0.16 0.068 0.3 1.4, 0.8 0.581
Survivor no adrenalectomy 0.9 12.0, 15.7 0.897 2.2 9.2, 5.4 0.568 1.9 10.8, 7.9 0.700
Survivor adrenalectomy 20.8 4.6, 39.4 0.010 3.9 3.8, 12.2 0.332 9.9 0.5, 21.2 0.063
CI = conﬁdence interval.
a t = 0 = baseline.
b t = 30 = 30 min after administration of Synacthen.
c t = 60 = 60 min after administration of Synacthen.
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oestrogens (b = 39.5, P = 0.036) and in the subanalysis
excluding survivors who were currently using corticoste-
roids (b = 46.4, P = 0.012). Adding the cumulative
dose of various chemotherapeutic agents and radiother-
apy to the model did not aﬀect the results (data not
shown).
3.3. Normal controls
To conﬁrm that 440 nmol/l is a correct cut-oﬀ value
for serum cortisol at t = 30 in subjects of this age group,
47 control subjects were evaluated. Mean cortisol level
at t = 30 in our controls was 662 nmol/l (range 417–
1200). Ninety-six percent (n = 45) of controls had serumcortisol levels higher than 440 nmol/l, 4% (n = 2) of con-
trols had levels below 440 nmol/l (419 nmol/l and
430 nmol/l). These subjects were further investigated
using an insulin tolerance test and then reached a peak
cortisol level of >550 nmol/l, indicating that adrenal
function in these subjects was suﬃcient. Fifteen percent
of controls had cortisol levels at t = 30 below 500 nmol/
l, versus 5% of survivors.
3.4. Adrenal insuﬃciency
In order to evaluate adrenal insuﬃciency, cortisol lev-
els at t = 30 after administration of Synacthen were ana-
lysed. None of the nephroblastoma or neuroblastoma
survivors had cortisol levels below 440 nmol/l at t = 30
300
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Fig. 1b. Synacthen-test. Data shown as mean (95% conﬁdence interval). To avoid overlapping spaces are introduced on the x-axis between
subgroups.
Table 3
Inﬂuence of baseline cortisol levels on metabolic parameters.
Cortisol (per 100 mmol/l)
b 95% Conﬁdence interval P-value
Glucose (%)a 0.90 0.00, 0.02 0.138
Insulin (pmol/l)a 1.86 4.52, 8.23 0.57
HOMAa 0.06 0.02, 0.10 0.008
Triglycerides (%) 10.52 6.61, 14.45 <0.001
HDL-C (mmol/l) 0.02 0.05, 0.00 0.105
LDL-C (mmol/l) 0.09 0.03, 0.15 0.004
Apo-B (g/l) 0.04 0.02, 0.06 <0.001
Corrected for: age, sex, SES, smoking status, diagnosis, body mass
index, abdominal radiotherapy, cumulative dose of anthracyclines,
vincristin, actinomycin and cyclophosphamide.
HOMA = Homoeostatic Model Assessment, HDL-C = high-density
lipoprotein-cholesterol, LDL-C = low-density lipoprotein-cholesterol.
a Subjects with diabetes excluded.
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diﬀerent between long-term survivors of nephroblas-
toma, neuroblastoma or controls. However, serum cor-
tisol levels at t = 30 and t = 60 were signiﬁcantly higher
in survivors after adrenalectomy compared with survi-
vors with both adrenals intact (Appendix Tables 1 and
2). Concordantly, mean increase of cortisol level after
Synacthen administration was lower in survivors after
adrenalectomy (210 nmol/l) compared with both con-
trols (mean 266, P = 0.034) and survivors with both
adrenals intact (mean 262, P = 0.032).3.5. Other adrenal steroids
DHEA, DHEAs, adione and 17-OHP were measured
both in males and females, testosterone was only mea-
sured in females, all at baseline, and after 30 and
60 min. All steroids in males followed a pattern similar
to that of cortisol. Steroids in females (oestrogen users
and non-oestrogen users) followed a somewhat less clear
pattern. For most steroids, baseline levels in adrenalec-
tomised patients were higher than in non-adrenalecto-
mised patients. However, no signiﬁcance was reached
(Appendix Table 3).3.6. Inﬂuence of baseline cortisol levels on metabolic
parameters
Baseline cortisol levels were positively associated with
triglyceride (P < 0.001), LDL-C (P = 0.004) and Apo-B
(P < 0.001) levels, but not with insulin or glucose levels.
However, association of baseline cortisol levels with
HOMA was signiﬁcant (P = 0.008) (Table 3).4. Discussion
The present study describes adrenal function in very
long-term (mean 27 years) adult survivors of childhood
nephroblastoma and neuroblastoma, in a substantial
subset of whom unilateral adrenalectomy was per-
formed. To our knowledge, this is the ﬁrst study in such
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blastoma survivors. We observed that all nephroblas-
toma and neuroblastoma survivors, regardless of the
presence of both or one adrenal gland(s), had adequate
adrenal function. It is therefore unlikely that adrenal
dysfunction contributes to the unexplained mortality
rate in childhood cancer survivors.
However, we unexpectedly found baseline cortisol and
ACTH levels to be higher in survivors treated with adre-
nalectomy comparedwith survivors treatedwithout adre-
nalectomy, and compared with healthy controls. Other
treatment components did not aﬀect the increased basal
cortisol and ACTH levels. In the normal population, cor-
tisol levels are known to be highly dependent on physical
(e.g. physical activity) or psychosocial (e.g. emotional
arousal) stress. It is possible that participating in this
study was more stressful for survivors, because of their
medical history, than for healthy controls. Raised cortisol
levels have been previously reported in childhood cancer
survivors after cranial irradiation.24 It could be that this
is explained by damaging the hypothalamus or pituitary,
or that raised cortisol levels are amore universal ﬁnding in
childhood cancer survivors, either explained by physical
or psychosocial stress. However, if that would be the
explanation, similar cortisol andACTH levels would then
have been expected in survivors treated without adrenal-
ectomy. The hypothesis of a higher ‘setpoint’ of the adre-
nal system in cases after adrenalectomy is therefore more
reasonable. The presence of both high ACTH levels and
high cortisol levels in survivors after adrenalectomy sug-
gests that the feedback systemhas been altered.Apossible
explanation for this higher setpoint could be that it is
achieved by a feedback loop of the neural pathways,
which might be damaged during surgery. Such a mecha-
nism has been described for the thyroid gland, which is
known to have neural connections with the hypothalamic
suprachiasmatic and paraventricular nuclei. Although
the speciﬁc role of autonomic innervation of the thyroid
gland in terms of endocrine regulation remains to be elu-
cidated, it is very likely that these connections contribute
to the coordination of metabolic control.25 Although the
pathogenesis of this possible higher setpoint is not clear
yet, it is important to realise that the presence of elevated
cortisol levels can inﬂuence the metabolic system in
this subset of survivors. Cortisol plays a role in
gluconeogenesis, suppresses the immune system, and is
involved in fat, protein and carbohydrate metabolism.
Higher prevalence of coronary calciﬁcation in young
andmiddle aged adults has beendescribed in subjectswith
more ﬂattened cortisol slopes, but not with average corti-
sol levels.26 In a large Dutch epidemiologic study total
cortisol exposure was associated with higher prevalence
of atherosclerosis as indicated by the number of plaques
in the carotid arteries.27We found baseline serum cortisol
levels to be positively associated with lipid concentrations
and insulin resistance. This indicates that the highersetpoint of theHPAaxismay inﬂuencemetabolic and car-
diovascular parameters in long-term childhood cancer
survivors and are therefore important confounders for
future studies.
In our study, adrenal function was assessed by a low-
dose ACTH stimulation test. This test is considered to
be superior to the 250 lg short ACTH stimulation test,
as 250 lg is a supraphysiological dose. This may lead to
overstimulation of partially atrophied adrenals, thereby
producing a deceivingly adequate cortisol response.20,28
So far, no consensus has been reached regarding the
cut-oﬀ value for peak cortisol levels after the low-dose
ACTH stimulation test. According to a meta-analysis
by Kazlauskaite et al. cortisol levels below 440 at 30 min
after administration of Synacthen are predictive of hypo-
thalamic-pituitary-adrenal insuﬃciency.20 The lack of a
standard cortisol assay method explains at least partly
the variability in diagnostic cortisol thresholds reported
across studies. For that reason andalso because large con-
trol groups of young adults tested for adrenal insuﬃ-
ciency are lacking, we felt that an age-matched control
group consisting of healthy subjects was mandatory to
strengthen our study. Results of the Synacthen-test in
our control subjects conﬁrm that 440 nmol/l is a correct
cut-oﬀ value in this group of survivors and controls.
Moreover, as 73% of the control subjects in this study
were relatives of the survivors, the possibly confounding
eﬀect of genetic variation is negligible.
Although 17-hydroxy-progesterone, adione, DHEA,
DHEAs and testosterone have, compared with cortisol,
only minor importance in the diagnosis of primary adre-
nal insuﬃciency, their levels as a reﬂection of normal
response to the low dose stimulation test provide further
proof of suﬃcient adrenal function and are in line with
our observed serum cortisol levels. In our study, levels of
these steroids correlated well with cortisol in males,
however in females this correlation was less strong. This
might be explained by the fact that we did not perform
the Synacthen-test on the same day of the menstrual
cycle of the females. It is known that the menstrual cycle
yields a varying ovarian contribution to the concentra-
tion of these steroids.29
In conclusion, long-term nephroblastoma and neuro-
blastoma survivors after unilateral adrenalectomy are
not at risk for adrenal insuﬃciency. However, we found
their baseline cortisol and ACTH levels to be elevated
compared with controls and survivors without adrenal-
ectomy. This higher setpoint can induce consequences
for the metabolic system and cardiovascular risk in these
survivors, which is suggested by our ﬁndings of elevated
lipid levels and increased insulin resistance. Our study
indicates that further studies on the exact mechanism
behind the altered setpoint of the adrenal system after
adrenalectomy are warranted. Detailed information on
the status of the adrenal glands after surgery is there-
fore of value in those studies. Moreover, studies on
1166 M. van Waas et al. / European Journal of Cancer 48 (2012) 1159–1166the inﬂuence of this higher baseline setting on metabolic
and cardiovascular parameters in subsets of long-term
adult survivors of childhood cancer are relevant.
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